Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7588383 | 1.00 | POLB (0.64) | POLBALDH1A1TSHRGAALMNA | |
| Hydrochloric Acid SCHEMBL10532450 | 0.98 | POLB (0.62) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL14433714 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL29838840 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL14493662 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL1058665 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL13589979 | 0.86 | POLB (0.75) | POLBALDH1A1TSHRGAALMNA | |
| SCHEMBL10532442 | 0.85 | GAA (0.51) | POLBALDH1A1TSHRGAATHRB | |
| SCHEMBL1786642 | 0.83 | MEN1 (0.53) | POLBALDH1A1TSHRLMNAMEN1 | |
| SCHEMBL14341836 | 0.81 | POLB (0.64) | POLBALDH1A1TSHRGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120318969-A1 | METHOD FOR THE DIFFERENTIATION OF ALTERNATIVE SOURCES OF NAPHTHENIC ACIDS | UNIVERSITY OF PLYMOUTH (GB) | 2012-12-20 | — | — | US | claimed |
| EP-0653065-B1 | SEPARATION METHOD | MARCONI OPTICAL COMPONENTS LTD (GB) | 2002-10-30 | — | — | EP | claimed |
| EP-0660935-B1 | IMMUNOLOGICAL DETECTION USING TWO DETECTABLE LABELS | MARCONI GEC LTD (GB) | 2000-05-24 | — | — | EP | claimed |
| US-5723304-A | Immunological detection using two detectable labels | GEC-MARCONI LIMITED (GB) | 1998-03-03 | — | — | US | claimed |
| EP-0660935-A1 | IMMUNOLOGICAL DETECTION USING TWO DETECTABLE LABELS | GEC-MARCONI LIMITED (GB) | 1995-07-05 | — | — | EP | claimed |
| EP-0653065-A1 | SEPARATION METHOD | GEC-MARCONI LIMITED (GB) | 1995-05-17 | — | — | EP | claimed |
| WO-1994003807-A1 | SEPARATION METHOD | GEC-MARCONI LIMITED (GB) | 1994-02-17 | — | — | WO | claimed |
| WO-1994003811-A1 | IMMUNOLOGICAL DETECTION USING TWO DETECTABLE LABELS | GEC-MARCONI LIMITED (GB) | 1994-02-17 | — | — | WO | claimed |
| JP-11040464-A | — | — | None | — | — | JP | disclosed |
| US-20210353652-A1 | TUMOR MICROENVIRONMENT-ACTIVATED DRUG-BINDER CONJUGATES, AND USES RELATED THERETO | AVACTA LIFE SCIENCES, LIMITED (GB) | 2021-11-18 | — | — | US | disclosed |
| US-20140147794-A1 | METHOD OF FORMING PHOTORESIST PATTERN | JSR CORPORATION (JP) | 2014-05-29 | — | — | US | disclosed |
| US-8535872-B2 | Thermally cured underlayer for lithographic application | FUJIFILM ELECTRONIC MATERIALS, U.S.A., INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8481016-B2 | Method for inhibition of potential-dependent cation channel | KAO CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| US-8435718-B2 | Upper layer-forming composition and photoresist patterning method | JSR CORPORATION (JP) | 2013-05-07 | — | — | US | disclosed |
| WO-1992000995-A1 | CYCLIC CELL ADHESION MODULATION COMPOUNDS | TANABE SEIYAKU CO. LTD. (JP) | 1992-01-23 | — | — | WO | disclosed |
| EP-0421802-A2 | 3-substituted-1,4-benzodiazepines useful as oxytocin antagonists | MERCK & CO. INC. (US) | 1991-04-10 | — | — | EP | disclosed |
| US-4781977-A | WATER-INSOLUBLE RESIN-SPACER-LIGAND | SANRAKU INCORPORATED (JP) | 1988-11-01 | — | — | US | disclosed |
| EP-0220719-A2 | Cyclodextrin absorbing material and its use | Sanraku Incorporated (JP) | 1987-05-06 | — | — | EP | disclosed |
| US-4349552-A | TREATMENT OF CANCER | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1982-09-14 | — | — | US | disclosed |
| EP-0010941-B1 | 5-FLUOROURACIL DERIVATIVES, PREPARATION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353652-A1 | TUMOR MICROENVIRONMENT-ACTIVATED DRUG-BINDER CONJUGATES, AND USES RELATED THERETO | CD47, VCAM1, CD44 | POLB 4129/4885ALDH1A1 1284/4885TSHR 2415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.